Sublingual Immunotherapy (Q84213706)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21621059 AND SRC:MED&resulttype=core&format=json

2 February 2020

review article

1 reference

title

Sublingual immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21621059 AND SRC:MED&resulttype=core&format=json

2 February 2020

Sublingual Immunotherapy (English)

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

3 December 2024

1 reference

Bryan Leatherman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21621059 AND SRC:MED&resulttype=core&format=json

2 February 2020

Sandra Y. Lin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21621059

3 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21621059

3 December 2024

publication date

1 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21621059 AND SRC:MED&resulttype=core&format=json

2 February 2020

June 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21621059

full work available at URL

3 December 2024

https://api.elsevier.com/content/article/PII:S0030666511000569?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

https://api.elsevier.com/content/article/PII:S0030666511000569?httpAccept=text/plain

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Otolaryngologic Clinics of North America

3 December 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21621059 AND SRC:MED&resulttype=core&format=json

2 February 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21621059 AND SRC:MED&resulttype=core&format=json

2 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21621059 AND SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

753-64, x-xi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21621059 AND SRC:MED&resulttype=core&format=json

Is allergy increasing?--early life influences

2 February 2020

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Allergic rhinitis update: Epidemiology and natural history.

3 December 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

The burden of allergic rhinitis

3 December 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Long-term clinical efficacy of grass-pollen immunotherapy

3 December 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study.

3 December 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study

3 December 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Allergic rhinitis and its impact on asthma

3 December 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Adverse reactions associated with skin testing and immunotherapy.

3 December 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Noninjection routes for immunotherapy

3 December 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite.

3 December 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997

3 December 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

3 December 2024

Local immunotherapy

13

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings

3 December 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial.

3 December 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications.

3 December 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis

3 December 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Immunomodulation during sublingual therapy in allergic children

3 December 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

[Sublingual immunotherapy with cat epithelial extract. Personal experience]

3 December 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis

3 December 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites

3 December 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study

3 December 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis

3 December 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis

3 December 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy

3 December 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Immunologic evaluation of 24 month course of sublingual immunotherapy

3 December 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Sublingual immunotherapy for allergic rhinitis

3 December 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Sublingual immunotherapy: a comprehensive review.

3 December 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method

3 December 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials

3 December 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Subcutaneous and sublingual immunotherapy in children: complete update on controversies, dosing, and efficacy

3 December 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis

3 December 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study

3 December 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study.

3 December 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.

3 December 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy

3 December 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Quality of life outcomes with sublingual immunotherapy

3 December 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Sublingual immunotherapy in polysensitized patients: effect on quality of life

3 December 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study

3 December 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study

3 December 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study

3 December 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Anaphylaxis to multiple pollen allergen sublingual immunotherapy

3 December 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet

3 December 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Anaphylaxis to sublingual immunotherapy

3 December 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results

3 December 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

European allergen extract units and potency: review of available information.

3 December 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Allergen immunotherapy: a practice parameter second update

3 December 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Sublingual Immunotherapy: Past, present, paradigm for the future? A review of the literature

3 December 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen

3 December 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents

3 December 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults

3 December 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study

3 December 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Comparison between continuous or intermittent schedules of sublingual immunotherapy for house dust mites: effects on compliance, patients satisfaction, quality of life and safety

3 December 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Sublingual immunotherapy in daily medical practice: effectiveness of different treatment schedules - IPD meta-analysis.

3 December 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet

3 December 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

Standards for practical allergen-specific immunotherapy

3 December 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.OTC.2011.03.012

3 December 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21621059 AND SRC:MED&resulttype=core&format=json

2 February 2020

1 reference